Crohn’s Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Dec. 1, 2011 - PRLog -- GlobalData has estimated that the global Crohn’s Disease (CD) therapeutics market was worth $3.6 billion in 2010, which grew at a compound annual growth rate (CAGR) of 25.2% from $1.2 billion in 2005. This high growth rate, during the period 2005-2010, was primarily attributed to the launch of biologics such as Humira (adalimumab), Cimzia (certolizumab pegol) and Tysabri (natalizumab) and the increased uptake of the biologics Remicade (Infliximab) and Entocort EC (budesonide). The CD therapeutics market is forecast to show moderate growth, at a CAGR of 2.6% for the next eight years, to reach $4.4 billion by 2018. This reduced growth will come as a result of the patent expiries of Remicade and Entocort EC and the subsequent launch of biosimilars in the forecast period. The CD therapeutics pipeline is strong, with first-in-class molecules in the late stage of development, which when launched are expected to off-set the generic incursion and drive the market.

GlobalData has analyzed the current competition in the CD therapeutics market and has found that it is becoming more intense due to the increased entry of biologics. Although only a small segment of people can use biologics, their use in the treatment of CD is significant,which is not the case for other autoimmune diseases. Johnson & Johnson’s Remicade (infliximab) is the market leader, which is followed by AstraZeneca/Prometheus’s Entocort EC (budesonide), Abbott’s Humira (adalimumab) and Biogen Idec’s Tysabri (natalizumab) respectively. There is increased competition between Remicade, Humira and the recently approved product UCB’s Cimzia (certolizumab pegol) to be the market leader. Tysabri has a different mechanism of action from the other biologics, but it is available only through the TOUCH prescribing program, which is a restricted distribution program and The global CD therapeutics market has seen intense competition, which is expected to further escalate in the coming years.

GlobalData has found that the CD therapeutics market has moderate unmet need with the available treatment options moderately successful in meeting the current market demand. Although there is no existing pharmacologic agent who can induce remission in all patients with CD and which can cure the disease. The existing therapeutics are competing to provide a rapid induction of remission, maintenance of remission, and mucosal healing. Biologics are usually prescribed for those patients with moderate to severe disease, to provide better clinical remission and to reduce further chances of surgery. However, safety remains a concern. There is significant scope for a new entrant which has better potential to address the early stages of disease and which can prevent further progression of disease. There is significant opportunity for any drug that can offer improved results or retain the efficacy provided by the current players but with increased safety.

For Sample Pages, please click or add the below link to your browser:
http://globaldata.com/reportstore/RequestSamplePages.aspx...

GlobalData analyzed that there are 46 molecules in various stages of the pipeline. First-in-class molecules (43) are dominant in the CD therapeutics pipeline. Traficet-EN (CCX282), Vedolizumab (MLN0002), Prochymal and Stelara are the late stage pipeline molecules. These pipeline molecules differ in their mechanism of action from the existing therapies, and are expected to offer better safety and may also provide clinical remission for a longer time. They may provide additional benefit to the patients who have become resistant to anti-tumor necrosis factor (TNF)-alpha therapies.
GlobalData, the industry analysis specialist, has released its new report, “Crohn’s Disease (CD)Therapeutics- Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Crohn’s Disease Therapeutics market. The report identifies the key trends shaping and driving the global Crohn’s Disease Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Crohn’s Disease Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://globaldata.com/reportstore/Report.aspx?ID=Crohns-D...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.